| CPAY |
Report |
Revenue |
BEAT |
pred ~$1.318B vs. cons $1.302B |
MEDIUM |
| CPAY |
Report |
Adjusted EPS |
BEAT |
pred ~$6.70 vs. cons $6.60 |
MEDIUM |
| CPAY |
Report |
Corporate Payments organic growth |
BEAT |
pred ~16.0% vs. cons 15.2% |
MEDIUM |
| CPAY |
Guide |
FY26 Revenue |
UNCHANGED |
guide ~$5.350B vs. cons $5.301B |
MEDIUM |
| CPAY |
Guide |
FY26 Adjusted EPS |
BETTER |
guide ~$27.10 vs. cons $26.79 |
MEDIUM |
| CPAY |
Guide |
Q3 Revenue |
BETTER |
guide ~$1.361B vs. cons $1.346B |
MEDIUM |
| CPAY |
Guide |
Q3 Adjusted EPS |
BETTER |
guide ~$7.15 vs. cons $7.03 |
MEDIUM |
| CPAY |
Guide |
Q3 Organic Revenue Growth |
BETTER |
guide ~10.0% vs. cons 9.4% |
MEDIUM |
| CPAY |
Return |
Day-1 residual (stock − beta × S&P 500) |
+6.5% |
— |
LOW |
| CPAY |
Return |
5-day cumulative residual |
+5.5% (FADE) |
FADE — positive estimate reset, tempered by setup |
LOW |